- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01788748
Evaluation of Fractional Bipolar Radiofrequency for the Treatment of Striae
Evaluation of Fractional Bipolar Radiofrequency, and Bipolar Radiofrequency Potentiated by Infrared, in Monotherapy or Combined, for the Treatment of Striae
This is an interventional open prospective randomized study, done in two sites.
The main purpose of this study is to evaluate the efficacy of the combination of bipolar radiofrequency potentiated by an infrared light followed by fractional bipolar radiofrequency for the treatment of striae on the abdomen.
In order to have a more complete and accurate study, each technology will also be evaluated separately. This will allow the comparison of the effect of each treatment, in monotherapy or combined.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stria is a very common condition that affects psychologically and aesthetically a lot of patients. It is a linear atrophic scar. So, to be treated, it needs to have both a superficial and a deep impact.
Several technologies have already been tested for this indication, but none of them have been proved at the same time effective and without a high risk of side effects for all skin types. As radiofrequency is an electrical current, it is not absorbed and does not see melanin. So it can be used on all skin types.
When using fractional bipolar radiofrequency, the current goes from small electrodes to return electrodes. Around the small electrodes appear some epidermal ablation, coagulation and deeper thermal damage. This means it has a superficial and a deep effect.
Using infrared combined with bipolar radiofrequency allows the infrared to pre-heat the skin so as to help the radiofrequency to go deeper in the skin more easily. This has a deep effect in the dermis.
In this study, both technologies will be used. At least 20 patients will be treated in two different sites.
The abdomen of each patient will be divided in four quadrants around the navel. Each quadrant will receive a total of three treatments one month apart:
- One quadrant will be the control (no treatment will be done)
- One quadrant will receive each time only bipolar radiofrequency potentiated by infrared
- One quadrant will receive each time only fractional bipolar radiofrequency
- One quadrant will receive each time first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency.
The choice of the treatment for each area will be randomized at the enrollment of the patient in the study.
There will be two follow-up sessions 3 and 6 months after the last treatment.
The evaluation will be done mainly by 3D acquisitions. This will allow measuring the length, width and depth of the striae and evaluating their evolution after the treatment.
Some patients, if they agree, will also have in vivo confocal microscopy before the first treatment and 6 months after the last one. This will give more information on the collagen and elastin changes.
Four patients, who accept it, will have biopsies performed before the first treatment and 6 months after the last one to also show the evolution of the skin structure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33200
- Aesthetics
-
Nice, France, 06200
- CHU Archet II, Service de Dermatologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subject over 18 years old, with striae on all the abdomen (white or red)
- Consent form signed by subjects
- Affiliation to social security
Exclusion Criteria:
- Electrical implants (pace maker, defibrillator) or superficial metallic implants (gold thread…)
- Pregnant woman
- Woman who can procreate without using an effective birth control
- Deficient immune system due to immunosuppressive diseases such as AIDS or HIV, or use of immunosuppressive drugs,
- Stretch marks resulting from treatment with steroids,
- Treatment with oral retinoids ongoing or stopped less than a year ago, or photosensitizing ongoing or stopped less than 3 months ago
- History of diseases stimulated by heat (recurrent herpes) on the treatment area
- Procedure less than 6 months ago performed on the treatment area,
- History of keloid scarring or difficulty in healing,
- History of allergy to xylocaine (for subjects who will have biopsy)
- Dermatological disorder requiring systemic therapy or local therapy in the area under study,
- Systemic disease in evolution (cancer or history of cancer, heart disease, uncontrolled diabetes, pain syndrome, history of neuropathy)
- Problem of coagulation and / or anticoagulant therapy,
- Vascular lesions or tattoos on the treatment area,
- Vulnerable Person: minor, under protection, deprived of liberty.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: bipolar radiofrequency and infrared
The abdomen of each patient will be divided in four quadrants around the navel.
One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
|
Other Names:
|
Active Comparator: fractional bipolar radiofrequency
The abdomen of each patient will be divided in four quadrants around the navel.
One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
|
Other Names:
|
Active Comparator: combined treatment
The abdomen of each patient will be divided in four quadrants around the navel.
One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of striae volume
Time Frame: before the first treatment, 3 and 6 months after the last treatment. Months 0, 5 and 8
|
The stretch marks in each area will be evaluated with a 3D camera (Antera 3D, Miravex).
This will give access to the length, width and depth of each stria.
Those measurements will then be compared so as to evaluate each technology.
|
before the first treatment, 3 and 6 months after the last treatment. Months 0, 5 and 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observation of the skin structure changes with in vivo confocal microscopy
Time Frame: 5 months
|
In vivo confocal microscopy acquisitions will be done on all subjects who agree to do so.
It is a non-invasive imaging procedure that shows the different structures of the skin (such as collagen fibers and elastin).
This will allow us to assess the effect of both technologies, used in monotherapy or combined, on those structures.
|
5 months
|
Observation of the skin structure changes with in vivo confocal microscopy
Time Frame: 8 months
|
In vivo confocal microscopy acquisitions will be done on all subjects who agree to do so.
It is a non-invasive imaging procedure that shows the different structures of the skin (such as collagen fibers and elastin).
This will allow us to assess the effect of both technologies, used in monotherapy or combined, on those structures.
|
8 months
|
Observation of the skin structure changes by histology
Time Frame: 8 months
|
For four patients, who previously agreed to do so, 3 biopsies will be done (one on each quadrant that will receive a treatment) before any treatment and at the 6 month follow-up session.
They will be analyzed in the anatomopathology laboratory of the Archet II hospital.
It will show the entire dermal and epidermal evolution after each type of treatment.
|
8 months
|
Pain assessment
Time Frame: 1 month
|
Pain will be assessed with an analogical visual scale.
|
1 month
|
Pain assessment
Time Frame: 2 months
|
Pain will be assessed with an analogical visual scale.
|
2 months
|
Global satisfaction
Time Frame: 1 month
|
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
|
1 month
|
Global satisfaction
Time Frame: 2 months
|
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
|
2 months
|
Double blinded pictures observation
Time Frame: 5 months
|
Standardized pictures will be taken at the beginning of each session.
Two external doctors will evaluate each picture on a Physician Global Assessment scale, without knowing to which session or to which subject it corresponds.
|
5 months
|
Double blinded pictures observation
Time Frame: 8 months
|
Standardized pictures will be taken at the beginning of each session.
Two external doctors will evaluate each picture on a Physician Global Assessment scale, without knowing to which session or to which subject it corresponds.
|
8 months
|
global satisfaction
Time Frame: 5 months
|
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
|
5 months
|
Global satisfaction
Time Frame: 8 months
|
The global satisfaction of both the subject and the investigator will be assessed with an analogical visual scale.
|
8 months
|
Pain assessment
Time Frame: first day
|
Pain will be assessed with an analogical visual scale.
|
first day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thierry Passeron, Pr, Hopital Archet II, service de Dermatologie
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRB-E2VER02
- 2012-A01427-36 (Other Identifier: ANSM (French health committee))
- 12.084 (Other Identifier: CPP Sud Méditerranée V (ethics committee))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Striae
-
First Affiliated Hospital of Jinan UniversityScience and Technology Program of GuangzhouUnknownTreatments of Striae GravidarumChina
-
Al-Azhar UniversityRecruiting
-
Kasr El Aini HospitalCompleted
-
Shahid Beheshti University of Medical SciencesCompletedExcimer Laser | White StriaeIran, Islamic Republic of
-
Jose R. Reyes Memorial Medical CenterCompletedStriae GravidarumPhilippines
-
American University of Beirut Medical CenterWellcome TrustCompleted
-
Brazilan Center for Studies in DermatologyCompletedTreatment | Striae | Stretch MarksBrazil
-
Mahidol UniversityUnknown
-
Ulthera, IncCompletedScars | StriaeUnited States
-
Ayca Solt KircaCompleted
Clinical Trials on bipolar radiofrequency and infrared
-
Assiut UniversityNot yet recruitingOsteoarthritis, Knee
-
Mansoura UniversityUnknownChronic Knee OsteoarthritisEgypt
-
Trod Medical N.V.Unknown
-
NYU Langone HealthTrod Medical N.V.CompletedProstate CancerUnited States
-
Cukurova UniversityCompleted
-
Xinqiao Hospital of ChongqingUnknownAtrial FibrillationChina
-
AtriCure, Inc.CompletedAtrial FibrillationUnited States
-
Norwegian University of Science and TechnologyUllevaal University Hospital; Oslo University Hospital; St. Olavs Hospital; Haukeland... and other collaboratorsWithdrawn
-
Medtronic Bakken Research CenterMedtronicTerminatedCoronary Artery Disease | Atrial FibrillationGermany
-
Beijing Anzhen HospitalXuanwu Hospital, Beijing; Beijing Chao Yang HospitalUnknownMI Related Malignant Ventricular ArrhythmiaChina